Careers  |  Sign In  |  Register

The Role of Multikinase TKIs for NSCLC

In this interview, Shirish M. Gadgeel, MD, MBBS, medical oncologist at Michigan Medicine, University of Michigan, provides insights into multikinase tyrosine kinase inhibitor (TKI) treatments and their varied observed efficacy in patients with different tumor types. In particular, he observes that multikinase TKIs appear to be more efficacious in medullary thyroid carcinoma with RET alterations than they are when targeting non-small cell lung cancer with RET alterations.

Read the full interview transcript by clicking here.

Faculty

D. Ross Camidge, MD, PhD
D. Ross Camidge, MD, PhD

Professor, Medicine - Medical Oncology

University of Colorado Cancer Center

Anschutz Medical Campus

Erin Schenk, MD, PhD
Erin Schenk, MD, PhD

Assistant Professor, Medicine - Medical Oncology

University of Colorado Cancer Center

Anschutz Medical Campus